The APOBEC3 family comprises seven different proteins (APOBEC3A [A3A] to A3H), which may act as strong mutators of proviral genomes. The accessory HIV protein Vif counteracts the antiviral activity of some but not all APOBEC3 variants. Although the global HIV-1 pandemic is driven by non-B subtypes, in particular subtype C, most data concerning the mode of action of Vif have been derived from subtype B molecular clones in conjunction with A3G. APOBEC3 molecules, however, differ not only in catalytic activity and expression but also in susceptibility to HIV-1 Vif mediated degradation. We hypothesize that broad spectrum Vif activity is the driving force for transmission/establishment of infection while suboptimal Vif activity is essential for emergence of escape variants and diversification in the later stages of disease. This hypothesis will be tested in three complementary specific aims using established and new assays. We will perform a comprehensive analysis of the function of pandemic, non-pandemic and patient- derived Vif alleles (Aim 1), dissect the relationship between Vif evolution and skewed proviral archives in patients (Aim 2), and determine the plasticity of Vif in forced selection experiments by passaging HIV in the presence of increasing APOBEC3 expression (Aim 2). Lastly, we will establish which APOBEC3 restricts viral spread of CXCR4 and CCR5 using viruses encoding mutant Vif variants in a humanized mouse model (Aim 3). These experiments will collectively establish the putative role of Vif as virulence factor, create "genotype to phenotype" assays to predict Vif activity in a subtype specific context and identify specific APOBEC3 proteins relevant for restriction and diversification in vivo. This knowledge will help in the discovery of drugs targeting this diverse viral-host interface and improve the already available treatment options by identifying patients at high risk for viral escape.
This proposal will investigate to what extent Vif alleles representative of all HIV subtypes and Vif variants derived directly from infected individuals differ in their anti-APOBEC3 activities and impact on viral diversification. These findings will allow for differential personalized treatment strategies adapted to the individual's own APOBEC3 repertoire.
|Hultquist, Judd F; Schumann, Kathrin; Woo, Jonathan M et al. (2016) A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. Cell Rep 17:1438-1452|
|Watanabe, Susan M; Simon, Viviana; Durham, Natasha D et al. (2016) The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility. Retrovirology 13:64|
|Reddy, Kavidha; Ooms, Marcel; Letko, Michael et al. (2016) Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes. AIDS 30:1723-9|
|D'arc, Mirela; Ayouba, Ahidjo; Esteban, Amandine et al. (2015) Origin of the HIV-1 group O epidemic in western lowland gorillas. Proc Natl Acad Sci U S A 112:E1343-52|
|Simon, Viviana; Bloch, Nicolin; Landau, Nathaniel R (2015) Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol 16:546-53|
|Letko, Michael; Booiman, Thijs; Kootstra, Neeltje et al. (2015) Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface. Cell Rep 13:1789-99|
|Zhao, Ke; Du, Juan; Rui, Yajuan et al. (2015) Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif. Cell Cycle 14:838-47|
|Dahabieh, Matthew S; Ooms, Marcel; Brumme, Chanson et al. (2014) Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFÎºB. Retrovirology 11:17|
|Opaluch, Amanda M; Schneider, Monika; Chiang, Chih-yuan et al. (2014) Positive regulation of TRAF6-dependent innate immune responses by protein phosphatase PP1-Î³. PLoS One 9:e89284|
|Brinzevich, Daria; Young, George R; Sebra, Robert et al. (2014) HIV-1 interacts with human endogenous retrovirus K (HML-2) envelopes derived from human primary lymphocytes. J Virol 88:6213-23|
Showing the most recent 10 out of 30 publications